ARA 290 (Cibinetide)

Muscle/RecoveryInnate Repair Receptor agonist / investigationalEmerging

Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis.

Calculate Dose

For research use only.

Key Facts

CAS: 1208243-63-3
Molecular Weight (MW): 1257.3 g/mol
Half-life: Short plasma half life (reported minutes; tissue protective signaling persists longer in models)
Unit: mg
Administration Route: Subcutaneous (most common in clinical trials)
Frequency: Once daily in many investigational studies
Last updated: 8/23/2026
Targets: Innate repair receptor (EPOR–βc)

Overview

Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis.

Protocol

Dosage Range: Dose dependent on clinical protocol; not established for general use
Frequency: Once daily in many investigational studies
Cycle: Investigational protocols vary; not established for consumer use
Administration Route: Subcutaneous (most common in clinical trials)
Reconstitution Guide: Reconstitute per supplier or clinical protocol instructions

Science

Mechanism of Action

11-amino-acid EPO-derived peptide that binds the innate repair receptor (EPOR/CD131) to trigger tissue-protective and anti-inflammatory signaling without hematopoietic EPO activity.